The investment firm already has a substantial share in Curaleaf’s $300-million senior loan facility deal, which the company closed in mid-January.
The Wakefield, Massachusetts-based medical and wellness cannabis operator manufactures a pharmaceutical-grade, standardized dose medical cannabis at 15 cultivation sites and 24 processing sites.
Its Curaleaf and Select brands are available in 57 dispensaries the company manages. It employs over 2,200 people across 17 states.
Don’t miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga’s first Virtual Cannabis Capital Conference on June 1.
“Curaleaf has quickly become a leader in a $16 billion industry through thoughtful acquisitions, licensing, product development, and expansion of retail dispensaries into new markets across the country,” Keith Stone, CapStone Holdings chairman and founder, said in a statement.
In early March, Curaleaf announced its purchase of Colorado edible producer BlueKudu. By obtaining BlueKudu, Curaleaf has expanded its assets to include an 8,400-square-foot infusion kitchen and processing facility located in Denver.
The acquisition of the three Arrow Alternative Care dispensaries in Connecticut came three weeks later, providing the company with dispensaries in Hartford, Milford and Stamford metro areas.
CapStone’s Heather Stone said the firm’s goal is to improve people’s quality of life, naming Curaleaf a “logical choice” considering the number of states where physicians are allowed to prescribe cannabis-based medicines to their patients.
Curaleaf shares were up 4.23% at $4.68 at the time of publication Monday.
Photo courtesy of Curaleaf.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.